Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025

Thu, May 1Earnings callSpeaker-labelled transcriptEli Lilly

No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).

Updated

Transcript

quotes of at most 25 words

Speaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.

3 matches for “Omvoh”; 3 quoted, at least 25 words apart.

Dave Rickscompanyprepared

…Q1 of 2024. Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than $4 billion and now account…

Dave Rickscompanyprepared

…the approval of Jaypirca in the EU for CLL, the approval of Omvoh in the U.S, EU and Japan for Crohn's disease and the initiation…

Lucas Montarcecompanyprepared

…plans that account for 60% of people who are commercially insured. For Omvoh, we have received approval of Crohn's disease across the globe as a…

Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP